Gilead Sciences Announces Third Quarter 2017 Financial Results
– Revised Full Year 2017 Guidance –
– Non-GAAP Diluted EPS of $2.27 per share –
– Diluted EPS of $2.06 per share –
– Product Sales of $6.4 billion –
FOSTER CITY, Calif.–(BUSINESS WIRE)– Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the third quarter ended September 30, 2017. The financial results that follow represent a year-over-year comparison of the third quarter 2017 to the third quarter 2016. Total revenues were $6.5 billion in 2017 compared to $7.5 billion in 2016. Net income was $2.7 billion or $2.06 per diluted share in 2017 compared to $3.3 billion or $2.49 per diluted share in 2016. Non-GAAP net income, which excludes amounts related to acquisition-related, up-front collaboration, stock-based compensation and other expenses, was $3.0 billion or $2.27 per diluted share in 2017 compared to $3.7 billion or $2.75 per diluted share in 2016.
| Three Months Ended | Nine Months Ended | ||||||||||||||
| September 30, | September 30, | ||||||||||||||
| (In millions, except per share amounts) | 2017 | 2016 | 2017 | 2016 | |||||||||||
| Product sales | $ | 6,402 | $ | 7,405 | $ | 19,825 | $ | 22,737 | |||||||
| Royalty, contract and other revenues | 110 | 95 | 333 | 333 | |||||||||||
| Total revenues | $ | 6,512 | $ | 7,500 | $ | 20,158 | $ | 23,070 | |||||||
| Net income attributable to Gilead | $ | 2,718 | $ | 3,330 | $ | 8,493 | $ | 10,393 | |||||||
| Non-GAAP net income* | $ | 2,990 | $ | 3,677 | $ | 9,311 | $ | 12,128 | |||||||
| Diluted earnings per share | $ | 2.06 | $ | 2.49 | $ | 6.44 | $ | 7.59 | |||||||
|
Non-GAAP diluted earnings per share* |
$ | 2.27 | $ | 2.75 | $ | 7.06 | $ | 8.87 | |||||||
* Non-GAAP net income and non-GAAP diluted earnings per share exclude acquisition-related, up-front collaboration, stock-based compensation and other expenses. A reconciliation between GAAP and non-GAAP financial information is provided in the tables on pages 7 and 8.
Product Sales
Total product sales for the third quarter of 2017 were $6.4 billion compared to $7.4 billion for the same period in 2016. Product sales for the third quarter of 2017 were $4.5 billion in the United States, $1.2 billion in Europe and $663 million in other locations. Product sales for the third quarter of 2016 were $5.1 billion in the United States, $1.4 billion in Europe and $931 million in other locations.
Antiviral Product Sales
Antiviral product sales, which include sales of our HIV, chronic hepatitis B (HBV) and chronic hepatitis C (HCV) products, were $5.8 billion for the third quarter of 2017 compared to $6.8 billion for the same period in 2016.
- HIV and HBV product sales were $3.6 billion compared to $3.5 billion for the same period in 2016. The increase was primarily due to the continued uptake of our tenofovir alafenamide (TAF) based products, Genvoya® (elvitegravir 150 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir alafenamide 10 mg), Descovy® (emtricitabine 200 mg/tenofovir alafenamide 25 mg) and Odefsey® (emtricitabine 200 mg/rilpivirine 25 mg/tenofovir alafenamide 25 mg).
- HCV product sales, which consist of Harvoni® (ledipasvir 90 mg/sofosbuvir 400 mg), Sovaldi® (sofosbuvir 400 mg), Epclusa® (sofosbuvir 400 mg/velpatasvir 100 mg) and Vosevi® (sofosbuvir 400 mg/velpatasvir 100 mg/voxilaprevir 100 mg), were $2.2 billion compared to $3.3 billion for the same period in 2016. The decline was due to lower sales of Harvoni and Sovaldi across all major markets, partially offset by sales of Epclusa, which was approved in the United States and Europe in June and July 2016, respectively, and sales of Vosevi, which was approved in the United States and Europe in July 2017.
Other Product Sales
Other product sales, which include Letairis® (ambrisentan), Ranexa® (ranolazine) and AmBisome® (amphotericin B liposome for injection), were $559 million for the third quarter of 2017 compared to $564 million for the same period in 2016.
Operating Expenses
| Three Months Ended | Nine Months Ended | ||||||||||||||
| September 30, | September 30, | ||||||||||||||
| (In millions) | 2017 | 2016 | 2017 | 2016 | |||||||||||
| Research and development expenses (R&D) | $ | 789 | $ | 1,141 | $ | 2,584 | $ | 3,890 | |||||||
| Non-GAAP R&D expenses* | $ | 745 | $ | 981 | $ | 2,446 | $ | 2,790 | |||||||
| Selling, general and administrative expenses (SG&A) | $ | 879 | $ | 831 | $ | 2,626 | $ | 2,406 | |||||||
| Non-GAAP SG&A expenses* | $ | 806 | $ | 780 | $ | 2,440 | $ | 2,256 | |||||||
* Non-GAAP R&D and SG&A expenses exclude acquisition-related, up-front collaboration, stock-based compensation and other expenses. A reconciliation between GAAP and non-GAAP financial information is provided in the tables on pages 7 and 8.
During the third quarter of 2017, compared to the same period in 2016:
- R&D expenses decreased primarily due to the 2016 impacts of a $200 million milestone expense associated with Nimbus Apollo, Inc. (Nimbus) and a $117 million impairment charge related to in-process R&D.
- Non-GAAP R&D expenses* decreased primarily due to the 2016 impact of a $200 million milestone expense associated with Nimbus.
Cash, Cash Equivalents and Marketable Securities
As of September 30, 2017, Gilead had $41.4 billion of cash, cash equivalents and marketable securities compared to $36.6 billion as of June 30, 2017. This increase was primarily due to the issuance of $3.0 billion aggregate principal amount of senior unsecured notes in September 2017 to partially fund the purchase of Kite Pharma, Inc. (Kite). The acquisition was completed in October 2017. Cash flow from operating activities was $2.7 billion for the quarter. During the third quarter of 2017, Gilead paid cash dividends of $682 million and utilized $153 million on stock repurchases.
Revised Full Year 2017 Guidance
Gilead revises its full year 2017 guidance, initially provided on February 7, 2017 and revised on July 26, 2017:
| (In millions, except percentages and per share amounts) | Initially Provided
February 7, 2017 Reiterated May 2, 2017 |
Updated
July 26, 2017 |
Updated October 26, 2017 |
|||||
| Net Product Sales | $22,500 – $24,500 | $24,000 – $25,500 | $24,500 – $25,500 | |||||
| Non-HCV Product Sales | $15,000 – $15,500 | $15,500 – $16,000 | $16,000 – $16,500 | |||||
| HCV Product Sales | $7,500 – $9,000 | $8,500 – $9,500 | $8,500 – $9,000 | |||||
| Non-GAAP* | ||||||||
| Product Gross Margin | 86% – 88% | 86% – 88% | 86% – 87% | |||||
| R&D Expenses | $3,100 – $3,400 | $3,200 – $3,400 | $3,300 – $3,400 | |||||
| SG&A Expenses | $3,100 – $3,400 | $3,200 – $3,400 | $3,300 – $3,400 | |||||
| Effective Tax Rate | 25.0% – 28.0% | 25.0% – 28.0% | 25.0% – 27.0% | |||||
| Diluted EPS Impact of Acquisition-related, Up-front Collaboration, Stock-based Compensation and Other Expenses | $0.84 – $0.91 | $0.86 – $0.93 | $1.02 – $1.17 |
* Non-GAAP Product Gross Margin, R&D and SG&A expenses and effective tax rate exclude acquisition-related, up-front collaboration, stock-based compensation and other expenses. A reconciliation between GAAP and non-GAAP full year 2017 guidance is provided in the tables on page 9.
Corporate Highlights
- In August, Gilead and Kite announced that the companies had signed a definitive agreement under which Gilead would acquire all of Kite’s outstanding shares of common stock for $180 per share in cash. The acquisition was completed in early October 2017 for approximately $11.2 billion, excluding $0.7 billion relating to the portion of stock-based compensation attributable to the post combination period.
Product and Pipeline Updates announced by Gilead during the Third Quarter of 2017 include:
Antiviral and Liver Diseases Programs
- Announced that the China Food and Drug Administration has approved Sovaldi for the treatment of HCV infection. Sovaldi was approved for the treatment of adults and adolescents (aged 12 to 18 years) infected with HCV genotype 1, 2, 3, 4, 5 or 6 as a component of a combination antiviral treatment regimen. Sovaldi is the first Gilead HCV medicine approved in China.
- Announced that the U.S. Food and Drug Administration (FDA) has granted priority review for Gilead’s new drug application (NDA) for an investigational, fixed-dose combination of bictegravir (50 mg) (BIC), an integrase strand transfer inhibitor, and emtricitabine/tenofovir alafenamide (200/25 mg) (FTC/TAF), a dual-NRTI backbone, for the treatment of HIV-1 infection. Gilead filed the NDA for BIC/FTC/TAF with a priority review voucher on June 12, 2017, and FDA has set a target action date under the Prescription Drug User Fee Act of February 12, 2018.
- Announced that FDA has approved expanded labeling for Epclusa, the first all-oral, pan-genotypic, once-daily single-tablet regimen for the treatment of adults with HCV infection, to include use in patients co-infected with HIV.
- Announced that the European Commission and FDA approved Vosevi, a once-daily single-tablet regimen for the treatment of HCV infection in adults with genotypes 1-6. Vosevi is the first and only single-tablet regimen for patients who have previously failed therapy with direct-acting antiviral (DAA) treatments and is the latest regimen in Gilead’s portfolio of sofosbuvir-based HCV DAA treatments.
- Announced detailed 48-week results from two Phase 3 studies evaluating the efficacy and safety of BIC/FTC/TAF for the treatment of HIV-1 infection in treatment-naïve adults. In the ongoing studies, BIC/FTC/TAF was found to be statistically non-inferior to regimens containing dolutegravir (50 mg). The data was presented in two late-breaker sessions at the 9th International AIDS Conference in Paris. In addition, our marketing authorization application for BIC/FTC/TAF has been fully validated and is now under evaluation by the European Medicines Agency.
Non-GAAP Financial Information
The information presented in this document has been prepared by Gilead in accordance with U.S. generally accepted accounting principles (GAAP), unless otherwise noted as non-GAAP. Management believes non-GAAP information is useful for investors, when considered in conjunction with Gilead’s GAAP financial information, because management uses such information internally for its operating, budgeting and financial planning purposes. Non-GAAP information is not prepared under a comprehensive set of accounting rules and should only be used to supplement an understanding of Gilead’s operating results as reported under GAAP. Non-GAAP measures may be defined and calculated differently by other companies in the same industry. A reconciliation between GAAP and non-GAAP financial information is provided in the tables on pages 7, 8 and 9.
Conference Call
At 4:30 p.m. Eastern Time today, Gilead’s management will host a conference call and a simultaneous webcast to discuss results from its third quarter 2017 and a general business update. To access the webcast live via the internet, please connect to the company’s website at www.gilead.com/investors 15 minutes prior to the conference call to ensure adequate time for any software download that may be needed to hear the webcast. Alternatively, please call 1-877-359-9508 (U.S.) or 1-224-357-2393 (international) and dial the conference ID 89229005 to access the call.
A replay of the webcast will be archived on the company’s website for one year, and a phone replay will be available approximately two hours following the call through October 28, 2017. To access the phone replay, please call 1-855-859-2056 (U.S.) or 1-404-537-3406 (international) and dial the conference ID 89229005.
About Gilead
Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company’s mission is to advance the care of patients suffering from life-threatening diseases. Gilead has operations in more than 30 countries worldwide, with headquarters in Foster City, California.
Forward-looking Statements
Statements included in this press release that are not historical in nature are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Gilead cautions readers that forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include: Gilead’s ability to achieve its anticipated full year 2017 financial results; Gilead’s ability to sustain growth in revenues for its antiviral and other programs; the risk that estimates of patients with HCV or anticipated patient demand may not be accurate; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including YescartaTM, Vosevi, Vemlidy, Epclusa, Descovy, Odefsey and Genvoya; Gilead’s ability to successfully commercialize Yescarta and advance Kite’s product pipeline and any difficulties or unanticipated expenses in connection with integrating the companies; the potential for increased pricing pressure globally and contracting pressure as well as decreased volume and market share from additional competitive HCV launches; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs) and Veterans Administration (VA); continued fluctuations in ADAP and VA purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead’s earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada outside the United States; potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead’s earnings; Gilead’s ability to submit new drug applications and receive regulatory approval for new product candidates in the timelines currently anticipated or at all, including for BIC/FTC/TAF; Gilead’s ability to successfully develop its oncology, inflammation, cardiovascular and respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead’s product candidates; Gilead’s ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead’s future revenues and pre-tax earnings; and other risks identified from time to time in Gilead’s reports filed with the U.S. Securities and Exchange Commission (SEC). In addition, Gilead makes estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses and related disclosures. Actual results may differ significantly from these estimates. You are urged to consider statements that include the words may, will, would, could, should, might, believes, estimates, projects, potential, expects, plans, anticipates, intends, continues, forecast, designed, goal, or the negative of those words or other comparable words to be uncertain and forward-looking. Gilead directs readers to its press releases, Quarterly Report on Form 10-Q for the quarter ended June 30, 2017 and other subsequent disclosure documents filed with the SEC. Gilead claims the protection of the Safe Harbor contained in the Private Securities Litigation Reform Act of 1995 for forward-looking statements.
All forward-looking statements are based on information currently available to Gilead, and Gilead assumes no obligation to update any such forward-looking statements.
Gilead owns or has rights to various trademarks, copyrights and trade names used in our business, including the following: GILEAD®, GILEAD SCIENCES®, AMBISOME®, CAYSTON®, COMPLERA®, DESCOVY®, EMTRIVA®, EPCLUSA®, EVIPLERA®, GENVOYA®, HARVONI®, HEPSERA®, LETAIRIS®, ODEFSEY®, RANEXA®, SOVALDI®, STRIBILD®, TRUVADA®, TYBOST®, VEMLIDY®, VIREAD®, VITEKTA®, VOLIBRIS®, VOSEVI®, YESCARTATM and ZYDELIG®.
ATRIPLA® is a registered trademark of Bristol-Myers Squibb & Gilead Sciences, LLC. LEXISCAN® is a registered trademark of Astellas U.S. LLC. MACUGEN® is a registered trademark of Eyetech, Inc. SUSTIVA® is a registered trademark of Bristol-Myers Squibb Pharma Company. TAMIFLU® is a registered trademark of Hoffmann-La Roche Inc.
For more information on Gilead Sciences, Inc., please visit www.gilead.com or call the Gilead Public Affairs Department at 1-800-GILEAD-5 (1-800-445-3235).
|
GILEAD SCIENCES, INC. CONDENSED CONSOLIDATED STATEMENTS OF INCOME (unaudited) (in millions, except per share amounts) |
||||||||||||||||
| Three Months Ended | Nine Months Ended | |||||||||||||||
| September 30, | September 30, | |||||||||||||||
| 2017 | 2016 | 2017 | 2016 | |||||||||||||
| Revenues: | ||||||||||||||||
| Product sales | $ | 6,402 | $ | 7,405 | $ | 19,825 | $ | 22,737 | ||||||||
| Royalty, contract and other revenues | 110 | 95 | 333 | 333 | ||||||||||||
| Total revenues | 6,512 | 7,500 | 20,158 | 23,070 | ||||||||||||
| Costs and expenses: | ||||||||||||||||
| Cost of goods sold | 1,032 | 1,129 | 3,115 | 3,186 | ||||||||||||
| Research and development expenses | 789 | 1,141 | 2,584 | 3,890 | ||||||||||||
| Selling, general and administrative expenses | 879 | 831 | 2,626 | 2,406 | ||||||||||||
| Total costs and expenses | 2,700 | 3,101 | 8,325 | 9,482 | ||||||||||||
| Income from operations | 3,812 | 4,399 | 11,833 | 13,588 | ||||||||||||
| Interest expense | (291 | ) | (242 | ) | (821 | ) | (699 | ) | ||||||||
| Other income (expense), net | 150 | 119 | 391 | 288 | ||||||||||||
| Income before provision for income taxes | 3,671 | 4,276 | 11,403 | 13,177 | ||||||||||||
| Provision for income taxes | 959 | 951 | 2,923 | 2,788 | ||||||||||||
| Net income | 2,712 | 3,325 | 8,480 | 10,389 | ||||||||||||
| Net loss attributable to noncontrolling interest | (6 | ) | (5 | ) | (13 | ) | (4 | ) | ||||||||
| Net income attributable to Gilead | $ | 2,718 | $ | 3,330 | $ | 8,493 | $ | 10,393 | ||||||||
| Net income per share attributable to Gilead common stockholders – basic | $ | 2.08 | $ | 2.52 | $ | 6.50 | $ | 7.72 | ||||||||
| Shares used in per share calculation – basic | 1,306 | 1,322 | 1,307 | 1,347 | ||||||||||||
| Net income per share attributable to Gilead common stockholders – diluted | $ | 2.06 | $ | 2.49 | $ | 6.44 | $ | 7.59 | ||||||||
| Shares used in per share calculation – diluted | 1,319 | 1,339 | 1,319 | 1,369 | ||||||||||||
| Cash dividends declared per share | $ | 0.52 | $ | 0.47 | $ | 1.56 | $ | 1.37 | ||||||||
|
GILEAD SCIENCES, INC. RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL INFORMATION (unaudited) (in millions, except percentages and per share amounts) |
||||||||||||||||
| Three Months Ended | Nine Months Ended | |||||||||||||||
| September 30, | September 30, | |||||||||||||||
| 2017 | 2016 | 2017 | 2016 | |||||||||||||
| Cost of goods sold reconciliation: | ||||||||||||||||
| GAAP cost of goods sold | $ | 1,032 | $ | 1,129 | $ | 3,115 | $ | 3,186 | ||||||||
| Acquisition-related- amortization of purchased intangibles | (209 | ) | (210 | ) | (629 | ) | (630 | ) | ||||||||
| Stock-based compensation expenses | (4 | ) | (4 | ) | (12 | ) | (11 | ) | ||||||||
| Other(1) | 2 | 3 | (18 | ) | 9 | |||||||||||
| Non-GAAP cost of goods sold | $ | 821 | $ | 918 | $ | 2,456 | $ | 2,554 | ||||||||
| Product gross margin reconciliation: | ||||||||||||||||
| GAAP product gross margin | 83.9 |
% |
84.8 |
% |
84.3 |
% |
86.0 |
% |
||||||||
| Acquisition-related- amortization of purchased intangibles | 3.3 |
% |
2.8 |
% |
3.2 |
% |
2.8 |
% |
||||||||
| Other(1) | — |
% |
— |
% |
0.1 |
% |
— |
% |
||||||||
| Non-GAAP product gross margin(2) | 87.2 |
% |
87.6 |
% |
87.6 |
% |
88.8 |
% |
||||||||
| Research and development expenses reconciliation: | ||||||||||||||||
| GAAP research and development expenses | $ | 789 | $ | 1,141 | $ | 2,584 | $ | 3,890 | ||||||||
| Up-front collaboration expenses | — | (5 | ) | — | (373 | ) | ||||||||||
| Acquisition-related expenses- acquired IPR&D | — | — | — | (400 | ) | |||||||||||
| Acquisition-related- IPR&D impairment | — | (117 | ) | — | (231 | ) | ||||||||||
| Stock-based compensation expenses | (53 | ) | (44 | ) | (142 | ) | (129 | ) | ||||||||
| Other(1) | 9 | 6 | 4 | 33 | ||||||||||||
| Non-GAAP research and development expenses | $ | 745 | $ | 981 | $ | 2,446 | $ | 2,790 | ||||||||
| Selling, general and administrative expenses reconciliation: | ||||||||||||||||
| GAAP selling, general and administrative expenses | $ | 879 | $ | 831 | $ | 2,626 | $ | 2,406 | ||||||||
| Acquisition-related- transaction costs | (12 | ) | — | (12 | ) | — | ||||||||||
| Stock-based compensation expenses | (56 | ) | (47 | ) | (150 | ) | (138 | ) | ||||||||
| Other(1) | (5 | ) | (4 | ) | (24 | ) | (12 | ) | ||||||||
| Non-GAAP selling, general and administrative expenses | $ | 806 | $ | 780 | $ | 2,440 | $ | 2,256 | ||||||||
| Operating margin reconciliation: | ||||||||||||||||
| GAAP operating margin | 58.5 |
% |
58.7 |
% |
58.7 |
% |
58.9 |
% |
||||||||
| Up-front collaboration expenses | — |
% |
0.1 |
% |
— |
% |
1.6 |
% |
||||||||
| Acquisition-related- amortization of purchased intangibles | 3.2 |
% |
2.8 |
% |
3.1 |
% |
2.7 |
% |
||||||||
| Acquisition-related expenses- acquired IPR&D | — |
% |
— |
% |
— |
% |
1.7 |
% |
||||||||
| Acquisition-related- IPR&D impairment | — |
% |
1.6 |
% |
— |
% |
1.0 |
% |
||||||||
| Acquisition-related- transaction costs | 0.2 |
% |
— |
% |
0.1 |
% |
— |
% |
||||||||
| Stock-based compensation expenses | 1.7 |
% |
1.3 |
% |
1.5 |
% |
1.2 |
% |
||||||||
| Other(1) | (0.1 | )% | (0.1 | )% | 0.2 |
% |
(0.1 | )% | ||||||||
| Non-GAAP operating margin(2) | 63.6 |
% |
64.3 |
% |
63.6 |
% |
67.1 |
% |
||||||||
| Interest expense reconciliation: | ||||||||||||||||
| GAAP interest expense | $ | (291 | ) | $ | (242 | ) | $ | (821 | ) | $ | (699 | ) | ||||
| Acquisition-related- transaction costs | 18 | — | 18 | — | ||||||||||||
| Non-GAAP interest expense | $ | (273 | ) | $ | (242 | ) | $ | (803 | ) | $ | (699 | ) | ||||
| Notes: | ||||||||||||||||
| (1) Amounts related to restructuring, contingent consideration, consolidation of a contract manufacturer and/or other individually insignificant amounts | ||||||||||||||||
| (2) Amounts may not sum due to rounding | ||||||||||||||||
|
GILEAD SCIENCES, INC. RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL INFORMATION – (Continued) (unaudited) (in millions, except percentages and per share amounts) |
||||||||||||||||
| Three Months Ended | Nine Months Ended | |||||||||||||||
| September 30, | September 30, | |||||||||||||||
| 2017 | 2016 | 2017 | 2016 | |||||||||||||
| Effective tax rate reconciliation: | ||||||||||||||||
| GAAP effective tax rate | 26.1 |
% |
22.2 |
% |
25.6 |
% |
21.2 |
% |
||||||||
| Up-front collaboration expenses | — |
% |
— |
% |
— |
% |
(0.5 | )% | ||||||||
| Acquisition-related- amortization of purchased intangibles | (1.2 | )% | (0.4 | )% | (1.2 | )% | (0.7 | )% | ||||||||
| Acquisition-related expenses- acquired IPR&D | — |
% |
— |
% |
— |
% |
(0.5 | )% | ||||||||
| Stock-based compensation expenses(1) | 0.8 |
% |
— |
% |
0.6 |
% |
— |
% |
||||||||
| Non-GAAP effective tax rate(2) | 25.7 |
% |
21.8 |
% |
25.0 |
% |
19.5 |
% |
||||||||
| Net income attributable to Gilead reconciliation: | ||||||||||||||||
| GAAP net income attributable to Gilead | $ | 2,718 | $ | 3,330 | $ | 8,493 | $ | 10,393 | ||||||||
| Up-front collaboration expenses | — | 5 | — | 373 | ||||||||||||
| Acquisition-related- amortization of purchased intangibles | 201 | 204 | 605 | 612 | ||||||||||||
| Acquisition-related expenses- acquired IPR&D | — | — | — | 400 | ||||||||||||
| Acquisition-related- IPR&D impairment | — | 74 | — | 173 | ||||||||||||
| Acquisition-related- transaction costs | 24 | — | 24 | — | ||||||||||||
| Stock-based compensation expenses(1) | 55 | 70 | 161 | 203 | ||||||||||||
| Other(3) | (8 | ) | (6 | ) | 28 | (26 | ) | |||||||||
| Non-GAAP net income attributable to Gilead | $ | 2,990 | $ | 3,677 | $ | 9,311 | $ | 12,128 | ||||||||
| Diluted earnings per share reconciliation: | ||||||||||||||||
| GAAP diluted earnings per share | $ | 2.06 | $ | 2.49 | $ | 6.44 | $ | 7.59 | ||||||||
| Up-front collaboration expenses | — | — | — | 0.27 | ||||||||||||
| Acquisition-related- amortization of purchased intangibles | 0.15 | 0.15 | 0.46 | 0.45 | ||||||||||||
| Acquisition-related expenses- acquired IPR&D | — | — | — | 0.29 | ||||||||||||
| Acquisition-related- IPR&D impairment | — | 0.06 | — | 0.13 | ||||||||||||
| Acquisition-related- transaction costs | 0.02 | — | 0.02 | — | ||||||||||||
| Stock-based compensation expenses(1) | 0.04 | 0.05 | 0.12 | 0.15 | ||||||||||||
| Other(3) | (0.01 | ) | — | 0.02 | (0.02 | ) | ||||||||||
| Non-GAAP diluted earnings per share(2) | $ | 2.27 | $ | 2.75 | $ | 7.06 | $ | 8.87 | ||||||||
| Non-GAAP adjustment summary: | ||||||||||||||||
| Cost of goods sold adjustments | $ | 211 | $ | 211 | $ | 659 | $ | 632 | ||||||||
| Research and development expenses adjustments | 44 | 160 | 138 | 1,100 | ||||||||||||
| Selling, general and administrative expenses adjustments | 73 | 51 | 186 | 150 | ||||||||||||
| Interest expense adjustments | 18 | — | 18 | — | ||||||||||||
| Total non-GAAP adjustments before tax | 346 | 422 | 1,001 | 1,882 | ||||||||||||
| Income tax effect(1) | (74 | ) | (74 | ) | (183 | ) | (151 | ) | ||||||||
| Other(3) | — | (1 | ) | — | 4 | |||||||||||
| Total non-GAAP adjustments after tax | $ | 272 | $ | 347 | $ | 818 | $ | 1,735 | ||||||||
| Notes: | ||||||||||||||||
| (1) Income tax effect related to stock-based compensation expenses for the three and nine months ended September 30, 2017 includes the incremental tax benefit of $27 million and $60 million, respectively, recognized from the adoption of Accounting Standards Update 2016-09 “Improvements to Employee Share-Based Payment Accounting” | ||||||||||||||||
| (2) Amounts may not sum due to rounding | ||||||||||||||||
| (3) Amounts related to restructuring, contingent consideration, consolidation of a contract manufacturer and/or other individually insignificant amounts | ||||||||||||||||
|
GILEAD SCIENCES, INC. RECONCILIATION OF GAAP TO NON-GAAP 2017 FULL YEAR GUIDANCE (unaudited) (in millions, except percentages and per share amounts) |
||||||
|
Initially |
Updated |
Updated |
||||
| Projected product gross margin GAAP to non-GAAP reconciliation: | ||||||
| GAAP projected product gross margin | 82% – 84% | 82% – 84% | 82% – 83% | |||
| Acquisition-related expenses(1)(3) | 4% – 4% | 4% – 4% | 4% – 4% | |||
| Non-GAAP projected product gross margin(2) | 86% – 88% | 86% – 88% | 86% – 87% | |||
| Projected research and development expenses GAAP to non-GAAP reconciliation: | ||||||
| GAAP projected research and development expenses | $3,295 – $3,640 | $3,410 – $3,655 | $3,535 – $3,685 | |||
| Stock-based compensation expenses(1)(3) | (180) – (195) | (195) – (210) | (220) – (240) | |||
| Acquisition-related expenses(1) / up-front collaboration expenses | (15) – (45) | (15) – (45) | (15) – (45) | |||
| Non-GAAP projected research and development expenses | $3,100 – $3,400 | $3,200 – $3,400 | $3,300 – $3,400 | |||
| Projected selling, general and administrative expenses GAAP to non-GAAP reconciliation: | ||||||
| GAAP projected selling, general and administrative expenses | $3,305 – $3,615 | $3,435 – $3,645 | $3,755 – $3,940 | |||
| Stock-based compensation expenses(1)(3) | (205) – (215) | (235) – (245) | (375) – (435) | |||
| Acquisition-related expenses- transaction costs and other(1) | — | — |
(80) – (105) |
|||
| Non-GAAP projected selling, general and administrative expenses | $3,100 – $3,400 | $3,200 – $3,400 | $3,300 – $3,400 | |||
| Projected diluted EPS impact of acquisition-related, up-front collaboration, stock-based compensation and other expenses: | ||||||
| Acquisition-related expenses(1) / up-front collaboration expenses | $0.62 – $0.67 | $0.62 – $0.67 | $0.72 – $0.82 | |||
| Stock-based compensation expenses(1) | 0.22 – 0.24 | 0.24 – 0.26 | 0.30 – 0.35 | |||
| Projected diluted EPS impact of acquisition-related, up-front collaboration, stock-based compensation and other expenses | $0.84 – $0.91 | $0.86 – $0.93 | $1.02 – $1.17 | |||
| Notes: | ||||||
| (1) Acquisition-related expenses, including acquisition-related amortization of intangible assets and stock-based compensation expenses, associated with Gilead’s acquisition of Kite are subject to adjustments pending completion of preliminary purchase accounting and valuation | ||||||
| (2) Total stock-based compensation expenses have a less than one percent impact on non-GAAP projected product gross margin | ||||||
| (3) Amounts include preliminary estimates of a range between $188 million and $251 million total stock-based compensation expenses associated with Gilead’s acquisition of Kite | ||||||
|
GILEAD SCIENCES, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited) (in millions) |
|||||||
| September 30, | December 31, | ||||||
| 2017 | 2016(1) | ||||||
| Cash, cash equivalents and marketable securities | $ | 41,360 | $ | 32,380 | |||
| Accounts receivable, net | 4,122 | 4,514 | |||||
| Inventories | 1,144 | 1,587 | |||||
| Property, plant and equipment, net | 3,100 | 2,865 | |||||
| Intangible assets, net | 8,342 | 8,971 | |||||
| Goodwill | 1,172 | 1,172 | |||||
| Other assets | 5,422 | 5,488 | |||||
| Total assets | $ | 64,662 | $ | 56,977 | |||
| Current liabilities | $ | 9,597 | $ | 9,218 | |||
| Long-term liabilities | 29,811 | 28,396 | |||||
| Stockholders’ equity(2) | 25,254 | 19,363 | |||||
| Total liabilities and stockholders’ equity | $ | 64,662 | $ | 56,977 | |||
| Notes: | |||||||
| (1) Derived from the audited consolidated financial statements as of December 31, 2016. Certain amounts have been reclassified to conform to current year presentation | |||||||
| (2) As of September 30, 2017, there were 1,307 million shares of common stock issued and outstanding | |||||||
|
GILEAD SCIENCES, INC. PRODUCT SALES SUMMARY (unaudited) (in millions) |
|||||||||||||||
| Three Months Ended | Nine Months Ended | ||||||||||||||
| September 30, | September 30, | ||||||||||||||
| 2017 | 2016 | 2017 | 2016 | ||||||||||||
| Antiviral products: | |||||||||||||||
| Genvoya – U.S. | $ | 810 | $ | 407 | $ | 2,189 | $ | 816 | |||||||
| Genvoya – Europe | 146 | 46 | 358 | 92 | |||||||||||
| Genvoya – Other International | 32 | 8 | 67 | 13 | |||||||||||
| 988 | 461 | 2,614 | 921 | ||||||||||||
| Harvoni – U.S. | 718 | 1,084 | 2,628 | 3,965 | |||||||||||
| Harvoni – Europe | 110 | 380 | 583 | 1,447 | |||||||||||
| Harvoni – Other International | 145 | 396 | 515 | 2,029 | |||||||||||
| 973 | 1,860 | 3,726 | 7,441 | ||||||||||||
| Epclusa – U.S. | 543 | 593 | 2,142 | 657 | |||||||||||
| Epclusa – Europe | 263 | 40 | 649 | 40 | |||||||||||
| Epclusa – Other International | 76 | 7 | 154 | 7 | |||||||||||
| 882 | 640 | 2,945 | 704 | ||||||||||||
| Truvada – U.S. | 604 | 573 | 1,635 | 1,780 | |||||||||||
| Truvada – Europe | 154 | 217 | 527 | 713 | |||||||||||
| Truvada – Other International | 53 | 68 | 175 | 205 | |||||||||||
| 811 | 858 | 2,337 | 2,698 | ||||||||||||
| Atripla – U.S. | 324 | 486 | 974 | 1,454 | |||||||||||
| Atripla – Europe | 79 | 129 | 259 | 412 | |||||||||||
| Atripla – Other International | 36 | 35 | 133 | 132 | |||||||||||
| 439 | 650 | 1,366 | 1,998 | ||||||||||||
| Descovy – U.S. | 241 | 65 | 682 | 114 | |||||||||||
| Descovy – Europe | 65 | 23 | 149 | 35 | |||||||||||
| Descovy – Other International | 10 | — | 22 | — | |||||||||||
| 316 | 88 | 853 | 149 | ||||||||||||
| Odefsey – U.S. | 255 | 95 | 688 | 164 | |||||||||||
| Odefsey – Europe | 37 | 10 | 87 | 10 | |||||||||||
| Odefsey – Other International | 4 | — | 6 | — | |||||||||||
| 296 | 105 | 781 | 174 | ||||||||||||
| Viread – U.S. | 137 | 155 | 395 | 420 | |||||||||||
| Viread – Europe | 55 | 77 | 202 | 234 | |||||||||||
| Viread – Other International | 82 | 71 | 237 | 208 | |||||||||||
| 274 | 303 | 834 | 862 | ||||||||||||
| Complera / Eviplera – U.S.(1) | 91 | 254 | 315 | 675 | |||||||||||
| Complera / Eviplera – Europe | 133 | 143 | 385 | 445 | |||||||||||
| Complera / Eviplera – Other International | 13 | 14 | 44 | 40 | |||||||||||
| 237 | 411 | 744 | 1,160 | ||||||||||||
| Stribild – U.S.(1) | 181 | 525 | 632 | 1,227 | |||||||||||
| Stribild – Europe | 40 | 78 | 161 | 243 | |||||||||||
| Stribild – Other International | 8 | 18 | 38 | 57 | |||||||||||
| 229 | 621 | 831 | 1,527 | ||||||||||||
| Sovaldi – U.S. | 32 | 363 | 120 | 1,783 | |||||||||||
| Sovaldi – Europe | 19 | 184 | 238 | 727 | |||||||||||
| Sovaldi – Other International | 168 | 278 | 489 | 950 | |||||||||||
| 219 | 825 | 847 | 3,460 | ||||||||||||
| Note: |
| (1) Amounts for the three and nine months ended September 30, 2016 include a favorable adjustment of rebate reserves of $223 million and $89 million for Stribild and Complera, respectively |
|
GILEAD SCIENCES, INC. PRODUCT SALES SUMMARY – (Continued) (unaudited) (in millions) |
|||||||||||||||
| Three Months Ended | Nine Months Ended | ||||||||||||||
| September 30, | September 30, | ||||||||||||||
| 2017 | 2016 | 2017 | 2016 | ||||||||||||
| Vosevi – U.S. | $ | 117 | $ | — | $ | 117 | $ | — | |||||||
| Vosevi – Europe | 5 | — | 5 | — | |||||||||||
| Vosevi – Other International | 1 | — | 1 | — | |||||||||||
| 123 | — | 123 | — | ||||||||||||
| Other Antiviral – U.S. | 48 | 14 | 101 | 36 | |||||||||||
| Other Antiviral – Europe | 7 | 5 | 17 | 18 | |||||||||||
| Other Antiviral – Other International | 1 | — | 4 | 2 | |||||||||||
| 56 | 19 | 122 | 56 | ||||||||||||
| Total antiviral products – U.S. | 4,101 | 4,614 | 12,618 | 13,091 | |||||||||||
| Total antiviral products – Europe | 1,113 | 1,332 | 3,620 | 4,416 | |||||||||||
| Total antiviral products – Other International | 629 | 895 | 1,885 | 3,643 | |||||||||||
| 5,843 | 6,841 | 18,123 | 21,150 | ||||||||||||
| Other products: | |||||||||||||||
| Letairis | 213 | 215 | 654 | 593 | |||||||||||
| Ranexa | 164 | 170 | 517 | 467 | |||||||||||
| AmBisome | 92 | 91 | 276 | 262 | |||||||||||
| Zydelig | 40 | 39 | 110 | 129 | |||||||||||
| Other | 50 | 49 | 145 | 136 | |||||||||||
| 559 | 564 | 1,702 | 1,587 | ||||||||||||
| Total product sales | $ | 6,402 | $ | 7,405 | $ | 19,825 | $ | 22,737 | |||||||
View source version on businesswire.com: http://www.businesswire.com/news/home/20171026006376/en/
Contacts
Gilead Sciences, Inc.
Investors
Robin Washington, 650-522-5688
Sung Lee, 650-524-7792
or
Media
Amy Flood, 650-522-5643